Peginterferon alfa-2a
Pegasys (peginterferon alfa-2a) is a protein pharmaceutical. Peginterferon alfa-2a was first approved as Pegasys on 2002-06-20. It is used to treat brain neoplasms, chronic hepatitis b, chronic hepatitis c, colorectal neoplasms, and cryoglobulinemia amongst others in the USA. It has been approved in Europe to treat chronic hepatitis b and chronic hepatitis c.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 1 more
Trade Name
FDA
EMA
Pegasys (discontinued: Pegasys)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Peginterferon alfa-2a
+
Ribavirin
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pegasys | Biologic Licensing Application | 2025-08-11 |
Indications
FDA
EMA
Show 17 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
710 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis | D006505 | — | K75.9 | 4 | 17 | 33 | 58 | 37 | 148 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 4 | 17 | 32 | 58 | 37 | 147 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 3 | 20 | 18 | 36 | 24 | 101 |
| Hepatitis c | D006526 | — | B19.2 | 2 | 11 | 22 | 38 | 24 | 97 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 2 | 5 | 13 | 23 | 12 | 54 |
| Hepatitis b | D006509 | — | — | 2 | 5 | 13 | 22 | 13 | 53 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 2 | 11 | 10 | 4 | 26 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 5 | 7 | 1 | — | 12 |
| Coinfection | D060085 | — | — | — | — | 2 | 1 | 1 | 4 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | — | 1 | 1 | 3 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 4 | 2 | — | 1 | 6 |
| Chronic hepatitis d | D019701 | — | — | — | 2 | 2 | — | 1 | 5 |
| Hepatitis d | D003699 | EFO_0007304 | — | — | 2 | 2 | — | 1 | 5 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 2 | — | 3 | 5 |
| Infections | D007239 | EFO_0000544 | — | — | 2 | 2 | — | — | 4 |
| Essential thrombocythemia | D013920 | — | D47.3 | 1 | 1 | 1 | — | — | 3 |
| Polycythemia vera | D011087 | — | D45 | 1 | 1 | 1 | — | — | 3 |
| Thrombocytosis | D013922 | — | D75.83 | 1 | 1 | 1 | — | — | 3 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 1 | 1 | 1 | — | — | 3 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 1 | 3 | — | — | 3 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Margins of excision | D000072662 | — | — | — | 1 | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 1 | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | 1 | — | — | — | 1 |
| Treatment failure | D017211 | — | — | — | 1 | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv | D006678 | — | O98.7 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Peginterferon alfa-2a |
| INN | peginterferon alfa-2a |
| Description | Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A) |
| Classification | Protein |
| Drug class | PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201560 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00008 |
| UNII ID | Q46947FE7K (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,670 documents
View more details
Safety
Black-box Warning
Black-box warning for: Pegasys
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
65,600 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use